var data={"title":"Basiliximab: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Basiliximab: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5703?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=basiliximab-drug-information\" class=\"drug drug_general\">see &quot;Basiliximab: Drug information&quot;</a> and <a href=\"topic.htm?path=basiliximab-patient-drug-information\" class=\"drug drug_patient\">see &quot;Basiliximab: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708643\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Experienced physician: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Only physicians experienced in immunosuppression therapy and management of organ transplantation patients should prescribe basiliximab. The physician responsible for basiliximab administration should have complete information requisite for the follow-up of the patient. Patients receiving the drug should be managed in facilities equipped with adequate laboratory and supportive medical resources.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F139095\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Simulect</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F139096\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Simulect</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F999831\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Monoclonal Antibody</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F999862\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=basiliximab-drug-information\" class=\"drug drug_general\">see &quot;Basiliximab: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Patients previously administered basiliximab should only be re-exposed to a subsequent course of therapy with extreme caution.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Infants, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Renal transplantation:</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Patient weight &lt;35 kg:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Initial dose: 10 mg administered within 2 hours prior to renal transplant surgery </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Second dose: 10 mg administered 4 days after transplantation; hold second dose if complications occur (including severe hypersensitivity reactions or graft loss) </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Patient weight &ge;35 kg: </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Initial dose: 20 mg administered within 2 hours prior to renal transplant surgery </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Second dose: 20 mg administered 4 days after transplantation; hold second dose if complications occur (including severe hypersensitivity reactions or graft loss) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Liver transplantation:</b>  IV: Limited data available (Cintorino, 2006; Kovarik, 2002; Spada, 2006):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Patient weight &lt;35 kg: </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Initial dose: 10 mg administered within 6 hours of organ perfusion </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Second dose: 10 mg administered 4 days after transplantation; hold second dose if complications occur (including severe hypersensitivity reactions or graft loss) </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Third dose: 10 mg has been repeated on postoperative days 8-10 if ascites fluid loss exceeds 70 mL/kg or &gt;5 L</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Patient weight &ge;35 kg: </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Initial dose: 20 mg administered within 6 hours of organ perfusion </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Second dose: 20 mg administered 4 days after transplantation; hold second dose if complications occur (including severe hypersensitivity reactions or graft loss) </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Third dose: 20 mg has been repeated on postoperative days 8-10 if ascites fluid loss exceeds 70 mL/kg or if total ascites volume &ge;5 L </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Heart transplantation:</b> IV: Limited data available (Ford, 2005; Grundy, 2009):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Patient weight &lt;35 kg: </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Initial dose: 10 mg administered immediately before cardiopulmonary by-pass started or within 6 hours of organ perfusion </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Second dose: 10 mg administered 4 days after transplantation; hold second dose if complications occur (including severe hypersensitivity reactions or graft loss) </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Patient weight &ge;35 kg: </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Initial dose: 20 mg administered immediately before cardiopulmonary by-pass started or within 6 hours of organ perfusion </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Second dose: 20 mg administered 4 days after transplantation; hold second dose if complications occur (including severe hypersensitivity reactions or graft loss) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Adults: <b>Renal transplantation:</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Initial dose: 20 mg administered within 2 hours prior to renal transplant surgery </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Second dose: 20 mg administered 4 days after transplantation; hold second dose if complications occur (including severe hypersensitivity reactions or graft loss) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Dosing adjustment in renal impairment: </b>There are no dosage adjustments provided in manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Dosing adjustment in hepatic impairment:</b>  There are no dosage adjustments provided in manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F139077\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Simulect: 10 mg (1 ea); 20 mg (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F139062\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F999868\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">For IV administration only. Administer only after assurance that patient will receive renal graft and immunosuppression. Reconstituted basiliximab solution may be administered without further dilution as a bolus injection over 10 minutes or further diluted and infused over 20 to 30 minutes. Bolus injection is associated with nausea, vomiting, and local pain at the injection site. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F139090\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store intact vials refrigerated at  2&deg;C to 8&deg;C (36&deg;F to 46&deg;F). Should be used immediately after reconstitution; however, if not used immediately, reconstituted solution  may  be stored at 2&deg;C to 8&deg;C for up to 24 hours or at room temperature for up to 4 hours. Discard the reconstituted solution if not used within 24 hours. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F999832\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">In combination with an immunosuppressive regimen (cyclosporine and corticosteroids), induction therapy for the prophylaxis of acute organ rejection in patients receiving renal transplants (FDA approved in pediatric patients [age not specified] and adults); basiliximab has also been used in liver and heart transplant patients</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25707942\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-4em;margin-left:6em;\">Basiliximab may be confused with bezlotoxumab.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes that have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F139130\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cardiovascular: Abnormal heart sounds, angina pectoris, atrial fibrillation, cardiac arrhythmia, cardiac failure, chest pain, hypertension, hypotension, peripheral edema, tachycardia, thrombosis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Central nervous system: Agitation, anxiety, depression, dizziness, fatigue, headache, hypoesthesia, insomnia, malaise, pain, rigors</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Dermatologic: Acne vulgaris, dermal ulcer, dermatological disease, hypertrichosis, pruritus, skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Endocrine &amp; metabolic: Acidosis, albuminuria, anasarca, dehydration, diabetes mellitus, hypercalcemia, hypercholesterolemia, hyperglycemia, hyperkalemia, hyperlipidemia, hypertriglyceridemia, hyperuricemia, hypervolemia, hypocalcemia, hypoglycemia, hypokalemia, hypomagnesemia, hyponatremia, hypophosphatemia, increased nonprotein nitrogen, increased serum glucocorticoids, weight gain </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gastrointestinal: Abdominal pain, constipation, diarrhea, dyspepsia, enlargement of abdomen, esophagitis, flatulence, gastroenteritis, gastrointestinal hemorrhage, GI moniliasis, gingival hyperplasia, hernia, melena, nausea, stomatitis (including ulcerative), vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Genitourinary: Bladder dysfunction, dysuria, genital edema (male), hematuria, impotence, oliguria, ureteral disease, urinary frequency, urinary retention, urinary tract infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hematologic &amp; oncologic: Anemia, hematoma, hemorrhage, hypoproteinemia, leukopenia, polycythemia, purpura, thrombocytopenia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Infection: Cytomegalovirus disease, herpes virus infection (simplex and zoster), infection, sepsis, viral infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Neuromuscular &amp; skeletal: Arthralgia, arthropathy, back pain, bone fracture, leg pain, muscle cramps, myalgia, neuropathy, paresthesia, tremor, weakness </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Ophthalmic: Cataract, conjunctivitis, visual disturbance</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Renal: Renal insufficiency, renal tubular necrosis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Respiratory: Bronchitis, bronchospasm, cough, dyspnea, pharyngitis, pneumonia, pulmonary edema, rhinitis, sinusitis, upper respiratory tract infection </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Miscellaneous: Accidental injury, cyst, fever, postoperative wound complication</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Rare but important or life-threatening: Anaphylaxis, capillary leak syndrome, cytokine release syndrome, diabetes (new onset), hypersensitivity reaction (includes bronchospasm, cardiac failure, dyspnea, hypotension, pruritus, pulmonary edema, respiratory failure, skin rash, sneezing, tachycardia, urticaria), impaired glucose tolerance, increase in fasting plasma glucose, lymphoproliferative disorder</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F139082\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Known hypersensitivity to basiliximab or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F139066\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anaphylactoid/hypersensitivity reactions: Severe hypersensitivity reactions, occurring within 24 hours, have been reported. Reactions, including anaphylaxis, have occurred both with the initial exposure and/or following re-exposure after several months; use caution during re-exposure to a subsequent course of therapy in a patient who has previously received basiliximab. Patients in whom concomitant immunosuppression was prematurely discontinued due to abandoned transplantation or early graft loss are at increased risk for developing a severe hypersensitivity reaction upon re-exposure. Discontinue permanently if a severe reaction occurs. Medications for the treatment of hypersensitivity reactions should be available for immediate use.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Diabetes: In renal transplant patients receiving basiliximab plus prednisone, cyclosporine, and mycophenolate, new-onset diabetes, glucose intolerance, and impaired fasting glucose were observed at rates significantly higher than observed in patients receiving prednisone, cyclosporine, and mycophenolate without basiliximab (Aasebo 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Human antimurine antibodies (HAMA): Treatment may result in the development of HAMA; however, limited evidence suggesting the use of muromonab-CD3 or other murine products is not precluded.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Lymphoproliferative disorders: The incidence of lymphoproliferative disorders may be increased by immunosuppressive therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Opportunistic infections: The incidence of opportunistic infections may be increased by immunosuppressive therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: To be used as a component of an immunosuppressive regimen which includes cyclosporine and corticosteroids.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Experienced physician: <b>[US Boxed Warning]: Should be administered under the supervision of a physician experienced in immunosuppression therapy and organ transplant management.</b></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298813\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F139071\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12842&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Belimumab: Monoclonal Antibodies may enhance the adverse/toxic effect of Belimumab. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Coccidioides immitis Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioides immitis Skin Test. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Echinacea: May diminish the therapeutic effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: Immunosuppressants may enhance the immunosuppressive effect of Fingolimod.  Management: Avoid the concomitant use of fingolimod and other immunosuppressants when possible. If combined, monitor patients closely for additive immunosuppressant effects (eg, infections).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nivolumab: Immunosuppressants may diminish the therapeutic effect of Nivolumab. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ocrelizumab: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pidotimod: Immunosuppressants may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tertomotide: Immunosuppressants may diminish the therapeutic effect of Tertomotide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or nonbiologic disease modifying antirheumatic drugs (DMARDs) is permitted, and this warning seems particularly focused on more potent immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).  Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F139073\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F139083\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">Adverse effects were not observed in animal reproduction studies. Basiliximab is a monoclonal IgG antibody which targets IL-2 receptors. IgG is known to cross the placenta; IL-2 receptors play an important role in the development of the immune system.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Women of childbearing potential should use effective contraceptive measures before beginning treatment, during, and for 4 months after completion of basiliximab treatment.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The National Transplantation Pregnancy Registry (NTPR) is a registry which follows pregnancies which occur in maternal transplant recipients or those fathered by male transplant recipients. The NTPR encourages reporting of pregnancies following solid organ transplant by contacting them at 877-955-6877 or NTPR@giftoflifeinstitute.org.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F999870\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">CBC with differential, vital signs, immunologic monitoring of T cells, renal function, serum glucose, signs or symptoms of hypersensitivity, infection </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7748980\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:0em;display:inline\">Serum concentration &gt;0.2 mcg/mL</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F139065\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Basiliximab is a chimeric (murine/human) immunosuppressant monoclonal antibody which blocks the alpha-chain of the interleukin-2 (IL-2) receptor complex; this receptor is expressed on activated T lymphocytes and is a critical pathway for activating cell-mediated allograft rejection</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F139081\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration: Mean: 36 days &plusmn; 14 days  (determined by IL-2R alpha saturation in patients also on cyclosporine and corticosteroids)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Mean: V<sub>d</sub>: Children 1 to 11 years: 4.8 &plusmn; 2.1 L; Adolescents 12 to 16 years: 7.8 &plusmn; 5.1 L; Adults: 8.6 &plusmn; 4.1 L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Children 1 to 11 years: 9.5 &plusmn; 4.5 days; Adolescents 12 to 16 years: 9.1 &plusmn; 3.9 days; Adults: Mean: 7.2 &plusmn; 3.2 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Clearance: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\"> Children 1 to 11 years: 17 &plusmn; 6 mL/hour; in pediatric liver transplant patients, significant basiliximab loss through ascites fluid can increase total body clearance and reduce IL-2R (CD25) saturation duration; dosage adjustments may be necessary (Cintorino 2006; Kovarik 2002; Spada 2006)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adolescents 12 to 16 years: 31 &plusmn;19 mL/hour</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults: 41 &plusmn; 19 mL/hour</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323008\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Simulect Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (1): $3,277.10</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (1): $4,301.22</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F139085\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Simulect (AE, AR, AT, AU, BB, BE, BG, BH, BR, CH, CL, CN, CO, CY, CZ, DE, DK, EC, EE, ES, FI, FR, GB, GR, HK, HN, HR, HU, ID, IE, IL, IN, IS, IT, JP, KR, KW, LB, LK, LT, LV, MT, MX, MY, NL, NO, NZ, PE, PH, PK, PL, PT, PY, QA, RO, RU, SA, SE, SG, SI, SK, TH, TR, TW, UY, VE, VN);</li>\n      <li>Simulekt (UA)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Aaseb&oslash; W, Midtvedt K, Valderhaug TG, et al, &quot;Impaired Glucose Homeostasis in Renal Transplant Recipients Receiving Basiliximab,&quot; <i>Nephrol Dial Transplant</i>, 2010, 25(4):1289-93.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/basiliximab-pediatric-drug-information/abstract-text/19934089/pubmed\" target=\"_blank\" id=\"19934089\">19934089</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bamgbola FO, Del Rio M, Kaskel FJ, et al, &quot;Non-Cardiogenic Pulmonary Edema During Basiliximab Induction in Three Adolescent Renal Transplant Patients,&quot; <i>Pediatr Transplant</i>, 2003, 7(4):315-20.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/basiliximab-pediatric-drug-information/abstract-text/12890011/pubmed\" target=\"_blank\" id=\"12890011\">12890011</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cintorino D, Riva S, Spada M, et al, &quot;Corticosteroid-Free Immunosuppression in Pediatric Liver Transplantation: Safety and Efficacy After a Short-Term Follow-Up,&quot; <i>Transplant Proc</i>, 2006, 38(4):1099-100.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/basiliximab-pediatric-drug-information/abstract-text/16757276/pubmed\" target=\"_blank\" id=\"16757276\">16757276</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dolan N, Waldron M, O'Connell M, et al, &quot;Basiliximab Induced Non-Cardiogenic Pulmonary Edema in Two Pediatric Renal Transplant Recipients,&quot; <i>Pediatr Nephrol</i>, 2009, 24(11):2261-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/basiliximab-pediatric-drug-information/abstract-text/19649661/pubmed\" target=\"_blank\" id=\"19649661\">19649661</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ford KA, Cale CM, Rees PG, et al, &quot;Initial Data on Basiliximab in Critically Ill Children Undergoing Heart Transplantation,&quot; <i>J Heart Lung Transplant</i>, 2005, 24(9):1284-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/basiliximab-pediatric-drug-information/abstract-text/16143246/pubmed\" target=\"_blank\" id=\"16143246\">16143246</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Goulet O, Sauvat F, Ruemmele F, et al, &quot;Results of the Paris Program: Ten Years of Pediatric Intestinal Transplantation,&quot; <i>Transplant Proc</i>, 2005, 37(4):1667-70.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/basiliximab-pediatric-drug-information/abstract-text/15919425/pubmed\" target=\"_blank\" id=\"15919425\">15919425</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Grundy N, Simmonds J, Dawkins H, et al, &quot;Pre-Implantation Basiliximab Reduces Incidence of Early Acute Rejection in Pediatric Heart Transplantation,&quot; <i>J Heart Lung Transplant</i>, 2009, 28(12):1279-84.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/basiliximab-pediatric-drug-information/abstract-text/19864164/pubmed\" target=\"_blank\" id=\"19864164\">19864164</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ji SQ, Chen HR, Yan HM, et al, &quot;Anti-CD25 Monoclonal Antibody (Basiliximab) for Prevention of Graft-Versus-Host Disease After Haploidentical Bone Marrow Transplantation for Hematological Malignancies,&quot; <i>Bone Marrow Transplant</i>, 2005, 36(4):349-54.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/basiliximab-pediatric-drug-information/abstract-text/15968293/pubmed\" target=\"_blank\" id=\"15968293\">15968293</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kovarik JM, Gridelli BG, Martin S, et al, &quot;Basiliximab in Pediatric Liver Transplantation: A Pharmacokinetic-Derived Dosing Algorithm,&quot; <i>Pediatr Transplant</i>, 2002, 6(3):224-30.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/basiliximab-pediatric-drug-information/abstract-text/12100507/pubmed\" target=\"_blank\" id=\"12100507\">12100507</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Spada M, Petz W, Bertani A, et al, &quot;Randomized Trial of Basiliximab Induction Versus Steroid Therapy in Pediatric Liver Allograft Recipients Under Tacrolimus Immunosuppression,&quot; <i>Am J Transplant</i>, 2006, 6(8):1913-21.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12842 Version 99.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708643\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F139095\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F139096\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F999831\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F999862\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F139077\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F139062\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F999868\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F139090\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F999832\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F25707942\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F139130\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F139082\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F139066\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298813\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F139071\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F139073\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F139083\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F999870\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F7748980\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F139065\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F139081\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323008\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F139085\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12842|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=basiliximab-drug-information\" class=\"drug drug_general\">Basiliximab: Drug information</a></li><li><a href=\"topic.htm?path=basiliximab-patient-drug-information\" class=\"drug drug_patient\">Basiliximab: Patient drug information</a></li></ul></div></div>","javascript":null}